Pages that link to "Q36038477"

The following pages link to A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth (Q36038477):

Displaying 27 items.

• Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study (Q28084489) (← links)
• Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells (Q33587034) (← links)
• Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression (Q33854515) (← links)
• Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies (Q35107009) (← links)
• CD8( ) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis (Q35655089) (← links)
• Fas expression by tumor stroma is required for cancer eradication (Q36598412) (← links)
• Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours (Q36638606) (← links)
• Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy (Q37370230) (← links)
• Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. (Q37492464) (← links)
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter (Q37529144) (← links)
• Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response (Q37542092) (← links)
• Inferring the Impact of Regulatory Mechanisms that Underpin CD8 T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation (Q37554202) (← links)
• Spleen cells from young but not old immunized mice eradicate large established cancers (Q37706396) (← links)
• Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model (Q37718304) (← links)
• Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals (Q38194489) (← links)
• Targeting cancer-specific mutations by T cell receptor gene therapy (Q38366556) (← links)
• The importance of the tumor microenvironment in the therapeutic management of cancer (Q38534294) (← links)
• MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. (Q39290133) (← links)
• Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. (Q39546521) (← links)
• Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. (Q40411216) (← links)
• Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer (Q42072059) (← links)
• Rejuvenated T cells attack old tumors (Q42097613) (← links)
• Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation (Q42573824) (← links)
• DNA vaccines for prostate cancer. (Q51142505) (← links)
• CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy (Q58565339) (← links)
• Cooperation of genes in HPV16 E6/E7-dependent cervico-vaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens (Q90714962) (← links)
• Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease (Q102334764) (← links)